Allison MC, Dhillon AP, Lewis WG, Pounder RE: Inflammatory bowel disease. 1998, London: Mosby, 9-95.
Podolsky DK: Inflammatory bowel disease. N Engl J Med. 2002, 347: 417-419. 10.1056/NEJMra020831.
Present DH: How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis. 2000, 6: 48-57. 10.1097/00054725-200002000-00009.
Hanauer SB: Medical therapy of ulcerative colitis. Gastroenterology. 2004, 126: 1582-1592. 10.1053/j.gastro.2004.02.071.
Truelove SC, Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955, 2: 1041-1048. 10.1136/bmj.2.4947.1041.
Truelove SC, Jewell DP: Intensive intravenous regimens for severe attacks of ulcerative colitis. Lancet. 1974, 1: 1067-1070.
Schulte CM: Review article: bone disease in inflammatory bowel disease. Aliment Pharmacol Ther. 2004, 20 (Suppl 4): 43-49.
Tripathi RC, Kipp MA, Tripathi BJ: Ocular toxicity of prednisone in pediatric patients with inflammatory bowel disease. Lens Eye Toxic Res. 1992, 9: 469-482.
Saag KG, Koehnke R, Caldwell JR: Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994, 96: 115-123. 10.1016/0002-9343(94)90131-7.
Saniabadi AR, Hanai H, Sawada K: Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003, 7: 48-59. 10.1046/j.1526-0968.2003.00012.x.
Heimann TM, Aufses AH: The role of peripheral lymphocytes in the prediction of recurrence in Crohn's disease. Surg Gynecol Obstet. 1985, 160: 295-298.
Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y: Selective neutrophil and monocyte adsorptive apheresis as a first line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci. 2004, 49: 565-571.
Aoki H, Nakamura K, Yoshimatsu Y, Shirai K, Suzuki Y: Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8 and the expression of toll like receptor 2 on granulocytes. Dig Dis Sci. 2007, 52: 1427-1433. 10.1007/s10620-006-9406-8.
McCarthy DA, Rampton DS, Liu Y-C: Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol. 1991, 86: 489-493. 10.1111/j.1365-2249.1991.tb02958.x.
Brannigan AE, O’Connell PR, Hurley H: Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock. 2000, 13: 361-366. 10.1097/00024382-200005000-00003.
Lee A, Whyte M, Haslett C: Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol. 1993, 54: 283-288.
Meagher LC, Cousin JM, Seckl JR, Haslett C: Opposing effects of glucocorticoids on the rate of appoptosis in neutrophilic and eosinophilic granulocytes. J Immunol. 1996, 156: 4422-4428.
Tibble JA, Sigthorsson G, Bridger D, Fagerhol MK, Bjarnason I: Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000, 119: 15-22. 10.1053/gast.2000.8523.
Schreiber S, Nikolaus S, Hampe J: Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet. 1999, 353: 459-461. 10.1016/S0140-6736(98)03339-X.
Papadakis KA, Targan SR: Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000, 51: 289-298. 10.1146/annurev.med.51.1.289.
Cassatella MA: The production of cytokines by polymorphonuclear neutrophils. Immunol Today. 1995, 16: 21-26. 10.1016/0167-5699(95)80066-2.
Nikolaus S, Bauditz J, Gionchetti P: Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut. 1998, 42: 470-476. 10.1136/gut.42.4.470.
Neurath MF: IL-23: a master regulator in Crohn’s disease. Nat Med. 2007, 13: 26-28. 10.1038/nm0107-26.
Shimoyama T, Sawada Y, Tanaka T: Granulocyte and monocyte apheresis in the treatment of active ulcerative colitis (Engl Abstr). Jpn J Apher. 1999, 18: 117-131.
Shimoyama T, Sawada K, Kashiwagi N, Saniabadi A: Safety and efficacy of granulocyte and monocyte apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher. 2001, 16: 1-9. 10.1002/jca.1000.
Panés J, Guilera M, Ginard D, Osa J, González-Carro P, González-Lara V, Varea V, Domènech E, Badia X: Treatment cost of ulcerative colitis: is apheresis with Adacolumn cost-effective?. Dig Liver Dis. 2007, 39: 617-625. 10.1016/j.dld.2007.03.007.
Domènech E, Hinojosa J, Esteve-Comas M, Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU): Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004, 20: 1347-1352. 10.1111/j.1365-2036.2004.02288.x.
Kanke K, Nakano M, Hiraishi H, Terano A: Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis. 2004, 36: 811-817. 10.1016/j.dld.2004.08.004.
Tanaka T, Okanobu H, Kuga Y: Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol. 2010, 34: 687-695.
Ljung T, Thomsen OØ, Vatn M: Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol. 2007, 42: 221-227. 10.1080/00365520600979369.
Sands BE, Sandborn WJ, Feagan B: A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008, 135: 400-409. 10.1053/j.gastro.2008.04.023.
Saniabadi AR, Hanai H, Sawada K: Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?. J Clin Apher. 2005, 20: 171-184. 10.1002/jca.20046.
Saniabadi AR, Hanai H, Fukunaga K: Therapeutic Leucocytapheresis for inflammatory bowel disease. Transf Apher Sci. 2007, 37: 191-200. 10.1016/j.transci.2007.08.003.
Yokoyama Y, Fukunaga K, Fukuda Y: Demonstration of low CD25High+CD4+ and high CD28-CD4+ T-cell subsets in patients with ulcerative colitis: modified by selective leucocytapheresis. Dig Dis Sci. 2007, 52: 2725-2731. 10.1007/s10620-006-9560-z.
Rachmilewitz D: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J. 1989, 298: 82-86. 10.1136/bmj.298.6666.82.
Yamamoto T: Granulocyte and monocyte adsorptive apheresis in the management of ulcerative colitis (Lttr). Aliment Pharmacol Ther. 2011, 33: 288-10.1111/j.1365-2036.2010.04521.x.
Hanai H, Watanabe F, Yamada M, Saniabadi A: Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid dependent moderately severe ulcerative colitis. Digestion. 2004, 70: 36-44. 10.1159/000080079.
Hanai H, Iida T, Taleuchi K: Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis. 2008, 40: 433-440. 10.1016/j.dld.2008.01.007.
Tanaka T, Okanobu H, Yoshimi S: Adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis. 2008, 40: 731-736. 10.1016/j.dld.2008.02.012.
Caprilli R, D'Ovidio V: Leukocytapheresis as promising therapy for inflammatory bowel disease. Dig Liver Dis. 2007, 39: 435-437. 10.1016/j.dld.2007.02.003.
Maiden L, Takeuchi K, Bjarnason I: Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis. 2008, 14: 1413-1418. 10.1002/ibd.20505.
Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A: Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis. 2007, 39: 430-434. 10.1016/j.dld.2007.01.001.
Suzuki Y, Yoshimura N, Saito Y, Saniabadi A: A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sc. 2006, 51: 2031-2038. 10.1007/s10620-006-9199-9.
Sakuraba A, Motoya S, Watanabe K: An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009, 104: 2990-2995. 10.1038/ajg.2009.453.